Skip to content

Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy

Justin C Strickland, Albert Garcia‐romeu, Matthew W. Johnson

ACS Pharmacology & Translational Science December 29, 2020 DOI: 10.1021/acsptsci.0c00187 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Within-subjects experimental crossover Randomized Peer reviewed
Sample size 10
Population Adult tobacco smokers receiving psilocybin for smoking cessation
Interventions Psilocybin Western classical music overtone-based music
Dose 20-30 mg/70 kg
Duration Two sessions with different music genres plus a third session with participant-chosen music
Topics Psilocybin Psychedelic-assisted therapy
Keywords Musical Music therapy Overtone Audiology Psychotherapist
Citations 89
Key findings Overtone-based music was associated with higher mystical experience scores and a slight benefit in smoking abstinence compared to Western classical music during psilocybin sessions.

Abstract

Mounting evidence supports the serotonin 2A receptor agonist psilocybin as a psychiatric pharmacotherapy. Little research has experimentally examined how session "set and setting" impacts subjective and therapeutic effects. We analyzed the effects of the musical genre played during sessions of a psilocybin study for tobacco smoking cessation. Participants (N = 10) received psilocybin (20-30 mg/70 kg) in two sessions, each with a different musical genre (Western classical versus overtone-based), with the order counterbalanced. Participants chose one genre for a third session (30 mg/70 kg). Mystical experiences scores tended to be higher in overtone-based sessions than in Western classical sessions. Six of ten participants chose the overtone-based music for a third session. Biologically confirmed smoking abstinence was similar based on musical choice, with a slight benefit for participants choosing the overtone-based playlist (66.7% versus 50%). These data call into question whether Western classical music typically used in psychedelic therapy holds a unique benefit. Broadly, we call for experimentally examining session components toward optimizing psychedelic therapeutic protocols.

Comparable studies

Other randomized controlled trials on psilocybin and psychedelic-assisted therapy, most cited first.

Study Year Design Participants
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Healthy adults, mostly hallucinogen-naïve 2011 Randomized controlled trial n = 18
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder Adults aged 25–65 with DSM-IV alcohol dependence and at least 4 heavy drinking days in... 2022 Randomized controlled trial n = 95
Increased global integration in the brain after psilocybin therapy for depression. Patients with treatment-resistant depression and patients with major depressive disorder 2022 Open-label trial and double-blind phase II randomized controlled trial
Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. Adults diagnosed with major depressive disorder and no unstable somatic conditions 2023 Double-blind, randomised clinical trial n = 52
Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin Healthy participants 2012 Randomized controlled trial n = 10

Explore topics

By condition and practice